Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04068181 |
Recruitment Status :
Active, not recruiting
First Posted : August 28, 2019
Last Update Posted : February 18, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Melanoma | Drug: Talimogene laherparepvec Drug: Pembrolizumab | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy |
Actual Study Start Date : | January 22, 2020 |
Estimated Primary Completion Date : | January 30, 2022 |
Estimated Study Completion Date : | July 31, 2024 |

Arm | Intervention/treatment |
---|---|
Experimental: Talimogene Laherparepvec and Pembrolizumab
To evaluate the efficacy and safety of talimogene laherparepvec in combination with pembrolizumab following disease progression on prior anti-PD-1 therapy in unresectable/metastatic melanoma (stage IIIB-IVM1d) or prior anti-PD-1 therapy in the adjuvant setting.
|
Drug: Talimogene laherparepvec
On day 1 the first dose of talimogene laherparepvec will be up to 4.0 mL of 10^6 PFU/mL by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions with or without image ultrasound guidance. The second dose of up to 4.0 mL of 10^8 PFU/mL talimogene laherparepvec will be administered 21 days after the initial dose. Subsequent doses of up to 4.0 mL of 10^8 PFU/mL talimogene laherparepvec will be given every 3 weeks. Drug: Pembrolizumab Pembrolizumab will be administered intravenously at a fixed dose of 200 mg every 3 weeks. |
- Overall response (Complete Response [CR] plus partial response [PR] by investigator assessment using modified Response Evaluation Criteria in Solid Tumor [RECIST v1.1]) [ Time Frame: Up to 4 years ]To evaluate the efficacy of talimogene laherparepvec in combination with pembrolizumab as assessed by Objective Response Rate (ORR) in subjects with unresectable/metastatic stage IIIB-IVM1d melanoma who have progressed on prior anti-PD-1 therapy.
- Complete Response by investigator assessment using modified Response Evaluation Criteria in Solid Tumor (RECIST v1.1) and modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST). [ Time Frame: Up to 4 years ]To evaluate the efficacy of talimogene laherparepvec in combination with pembrolizumab, as assessed by Complete Response Rate.
- Best Overall Response (BOR) by investigator assessment using modified Response Evaluation Criteria in Solid Tumor (RECIST v1.1) and modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST). [ Time Frame: Up to 4 years ]To evaluate the efficacy of talimogene laherparepvec in combination with pembrolizumab, as assessed by Best Overall Response.
- Durable Response by investigator assessment using modified Response Evaluation Criteria in Solid Tumor (RECIST v1.1) and modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST). [ Time Frame: Up to 4 years ]To evaluate the efficacy of talimogene laherparepvec in combination with pembrolizumab, as assessed by Durable Response Rate.
- Duration Of Response (DOR) by investigator assessment using modified Response Evaluation Criteria in Solid Tumor (RECIST v1.1) and modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST). [ Time Frame: Up to 4 years ]To evaluate the efficacy of talimogene laherparepvec in combination with pembrolizumab, as assessed by Duration Of Response.
- Disease Control by investigator assessment using modified Response Evaluation Criteria in Solid Tumor (RECIST v1.1) and modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST). [ Time Frame: Up to 4 years ]To evaluate the efficacy of talimogene laherparepvec in combination with pembrolizumab, as assessed by Disease Control Rate.
- Overall Response by investigator assessment using modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST). [ Time Frame: Up to 4 years ]To evaluate the efficacy of talimogene laherparepvec in combination with pembrolizumab, as assessed by Objective Response Rate using modified irRC-RECIST.
- Progression Free Survival (PFS) by investigator assessment using modified Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 and modified immune-related Response Criteria simulating Response evaluation criteria in Solid Tumors (irRC-RECIST). [ Time Frame: Up to 4 years ]To evaluate the efficacy of talimogene laherparepvec in combination with pembrolizumab, as assessed by Progression Free Survival.
- Overall Survival (OS) [ Time Frame: Up to 4 years ]To evaluate the efficacy of talimogene laherparepvec in combination with pembrolizumab, as assessed by Overall Survival.
- Incidence of treatment-emergent adverse events. [ Time Frame: Up to 4 years ]To evaluate the safety of talimogene laherparepvec in combination with pembrolizumab as assessed by incidence of treatment emergent adverse events in patients who have progressed on prior anti-PD-1 therapy.
- Incidence of treatment related adverse events. [ Time Frame: Up to 4 years ]To evaluate the safety of talimogene laherparepvec in combination with pembrolizumab as assessed by incidence of treatment-related adverse events in patients who have progressed on prior anti-PD-1 therapy.
- Incidence of abnormal laboratory tests. [ Time Frame: Up to 4 years ]To evaluate the safety of talimogene laherparepvec in combination with pembrolizumab as assessed by abnormal laboratory tests in patients who have progressed on prior anti-PD-1 therapy.
- Time to subsequent anti-cancer therapy. [ Time Frame: Up to 4 years ]To evaluate time to subsequent anti-cancer therapy.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Age ≥ 18 years with histologically confirmed diagnosis of stage IIIB to IVM1d melanoma and for whom surgery is not recommended. Subjects with stage IVM1d disease may be enrolled with up to 3 cerebral metastases, provided that all lesions have been adequately treated with stereotactic radiation therapy, craniotomy, or gamma knife therapy, with no evidence of progression and not requiring steroids for at least 2 months prior to enrollment.
- Subjects must have measurable disease and be a candidate for intralesional therapy administration into cutaneous, subcutaneous, or nodal lesions.
- Subjects must have had prior treatment (for at least 2 to 3 consecutive cycles within an 8 week period) with a PD-1 inhibitor and have confirmed disease progression (as defined by RECIST v1.1 criteria). The anti-PD-1 therapy must be the immediate prior line of therapy before enrollment and subjects with disease progression on more than 1 line of anti-PD-1 therapy are not eligible.
- ECOG performance status of 0 or 1.
- Adequate hematologic, renal, hepatic, and coagulation function.
Key Exclusion Criteria:
- Subjects considered by the investigator to have rapid clinical progression due to melanoma
- Subjects with prior treatment and disease progression on more than 1 line of anti-PD-1 therapy
- Stage IVM1d subjects must not have greater than 3 cerebral melanoma metastases, or clinically active cerebral melanoma metastases requiring therapy, and/or carcinomatous meningitis regardless of clinical stability.
- Primary uveal or mucosal melanoma, history or evidence of melanoma associated with immunodeficiency states or history of other malignancy within the past 3 years.
- Subjects must not have history or evidence of symptomatic autoimmune glomerulonephritis, vasculitis, or other symptomatic autoimmune disease, or active autoimmune disease or syndrome requiring systemic treatment in the past 2 years (ie, with use of disease modifying agents, steroids or immunosuppressive agents) except vitiligo or resolved childhood asthma/atopy, or evidence of clinically significant immunosuppression.
- Subjects may not have been previously treated with talimogene laherparepvec or any other oncolytic virus.
- Subjects must not have active herpetic skin lesions or prior complications of herpetic infection and must not require intermittent or chronic treatment with an antiherpetic drug (eg, acyclovir), other than intermittent topical use.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04068181
United States, California | |
Research Site | |
Santa Barbara, California, United States, 93105 | |
United States, Delaware | |
Research Site | |
Newark, Delaware, United States, 19713 | |
United States, Florida | |
Research Site | |
Orlando, Florida, United States, 32806 | |
United States, Kentucky | |
Research Site | |
Louisville, Kentucky, United States, 40202 | |
United States, Minnesota | |
Research Site | |
Fridley, Minnesota, United States, 55432 | |
United States, New York | |
Research Site | |
Albany, New York, United States, 12208 | |
United States, Ohio | |
Research Site | |
Cleveland, Ohio, United States, 44195 | |
United States, Texas | |
Research Site | |
Austin, Texas, United States, 78731 | |
Research Site | |
Dallas, Texas, United States, 75246 | |
Research Site | |
The Woodlands, Texas, United States, 77380 | |
Australia, New South Wales | |
Research Site | |
North Sydney, New South Wales, Australia, 2060 | |
Australia, Queensland | |
Research Site | |
Southport, Queensland, Australia, 4215 | |
Australia, South Australia | |
Research Site | |
Woodville South, South Australia, Australia, 5011 | |
Australia, Victoria | |
Research Site | |
Melbourne, Victoria, Australia, 3000 | |
Research Site | |
Melbourne, Victoria, Australia, 3004 | |
Canada, Ontario | |
Research Site | |
Toronto, Ontario, Canada, M5G 2M9 | |
Canada, Quebec | |
Research Site | |
Montreal, Quebec, Canada, H3T 1E2 | |
Canada | |
Research Site | |
Quebec, Canada, G1R 2J6 | |
France | |
Research Site | |
Bordeaux, France, 33075 | |
Research Site | |
Grenoble Cedex 9, France, 38043 | |
Research Site | |
Nantes Cedex 1, France, 44093 | |
Research Site | |
Paris, France, 75010 | |
Research Site | |
Pierre Benite Cedex, France, 69495 | |
Research Site | |
Villejuif, France, 94805 | |
Germany | |
Research Site | |
Berlin, Germany, 10117 | |
Research Site | |
Dresden, Germany, 01307 | |
Research Site | |
Hannover, Germany, 30625 | |
Research Site | |
Regensburg, Germany, 93053 | |
Research Site | |
Tübingen, Germany, 72076 | |
Greece | |
Research Site | |
Athens, Greece, 11527 | |
Research Site | |
Ioannina, Greece, 45500 | |
Research Site | |
Thessaloniki, Greece, 546 22 | |
Italy | |
Research Site | |
Bergamo, Italy, 24127 | |
Research Site | |
Meldola FC, Italy, 47014 | |
Research Site | |
Milano, Italy, 20141 | |
Netherlands | |
Research Site | |
Amsterdam, Netherlands, 1066 CX | |
Research Site | |
Rotterdam, Netherlands, 3015 GD | |
Poland | |
Research Site | |
Gdansk, Poland, 80-214 | |
Research Site | |
Poznan, Poland, 60-780 | |
Research Site | |
Warszawa, Poland, 02-781 | |
Spain | |
Research Site | |
Malaga, Andalucía, Spain, 29010 | |
Research Site | |
San Sebastian, País Vasco, Spain, 20014 | |
Research Site | |
Barcelona, Spain, 08035 | |
Research Site | |
Madrid, Spain, 28046 | |
Research Site | |
Madrid, Spain, 28050 | |
United Kingdom | |
Research Site | |
London, United Kingdom, SE1 9RT | |
Research Site | |
London, United Kingdom, SW3 6JJ |
Study Director: | MD | Amgen |
Responsible Party: | Amgen |
ClinicalTrials.gov Identifier: | NCT04068181 |
Other Study ID Numbers: |
20180115 2019-001906-61 ( EudraCT Number ) |
First Posted: | August 28, 2019 Key Record Dates |
Last Update Posted: | February 18, 2021 |
Last Verified: | February 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) |
Time Frame: | Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorizationin both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study. |
Access Criteria: | Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below. |
URL: | http://www.amgen.com/datasharing |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Melanoma Talimogene Laherparepvec Pembrolizumab Oncolytic immunotherapy |
Anti-PD-1 Checkpoint inhibitor MASTERKEY-115 |
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms |
Neoplasms, Nerve Tissue Nevi and Melanomas Pembrolizumab Talimogene laherparepvec Antineoplastic Agents, Immunological Antineoplastic Agents |